AR056733A1 - Uso de vacunas para el tratamiento / prevencion de la transmision de patogenos - Google Patents
Uso de vacunas para el tratamiento / prevencion de la transmision de patogenosInfo
- Publication number
- AR056733A1 AR056733A1 ARP060104694A ARP060104694A AR056733A1 AR 056733 A1 AR056733 A1 AR 056733A1 AR P060104694 A ARP060104694 A AR P060104694A AR P060104694 A ARP060104694 A AR P060104694A AR 056733 A1 AR056733 A1 AR 056733A1
- Authority
- AR
- Argentina
- Prior art keywords
- animal
- species
- prevention
- transmission
- vaccines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Método para la prevencion de la transmision de un patogeno , como por ejemplo el virus de la gripe aviar, de un animal de una primera especie a un animal de una segunda especie caracterizado porque el antígeno de un patogeno de un animal de una primera especie es utilizado para la inmunizacion de un animal de una segunda especie contra el patogeno del animal de la primera especie, donde la administracion de dicho antígeno de como resultado la reduccion o la ausencia de la reproduccion del patogeno del animal de la primera especie en un animal de la segunda especie.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73099805P | 2005-10-28 | 2005-10-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056733A1 true AR056733A1 (es) | 2007-10-17 |
Family
ID=38006396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060104694A Withdrawn AR056733A1 (es) | 2005-10-28 | 2006-10-27 | Uso de vacunas para el tratamiento / prevencion de la transmision de patogenos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8883123B2 (es) |
| EP (1) | EP1942924B1 (es) |
| JP (1) | JP2009513667A (es) |
| KR (1) | KR20080065680A (es) |
| CN (2) | CN102406932A (es) |
| AR (1) | AR056733A1 (es) |
| AT (1) | ATE543512T1 (es) |
| AU (1) | AU2006309007A1 (es) |
| BR (1) | BRPI0617952A2 (es) |
| CA (1) | CA2626866A1 (es) |
| TW (1) | TW200731986A (es) |
| WO (1) | WO2007053446A2 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200731986A (en) | 2005-10-28 | 2007-09-01 | Boehringer Ingelheim Vetmed | Use of vaccines for the treatment/prevention of the transmission of pathogens |
| US8202967B2 (en) * | 2006-10-27 | 2012-06-19 | Boehringer Ingelheim Vetmedica, Inc. | H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use |
| US20090246226A1 (en) * | 2008-03-28 | 2009-10-01 | Zeon Corporation | Avian vaccines possessing a positive marker gene |
| DE102008002641A1 (de) * | 2008-06-25 | 2009-12-31 | Biotronik Vi Patent Ag | Faserstrang und implantierbarer Stützkörper mit einem Faserstrang |
| JP5343079B2 (ja) * | 2008-08-18 | 2013-11-13 | 北里第一三共ワクチン株式会社 | トリインフルエンザウイルス抗原及び経口投与で有効な粘膜アジュバントを併用したトリインフルエンザワクチンの追加免疫方法 |
| RU2528750C2 (ru) * | 2008-11-19 | 2014-09-20 | Лабораторио Ави-Мекс, С.А. Де С.В. | Рекомбинантная вакцина на основе инактивированного вирусного вектора |
| MY159543A (en) | 2008-11-28 | 2017-01-13 | Merial Inc | Recombinant avian influenza vaccine and uses thereof |
| AR088028A1 (es) * | 2011-08-15 | 2014-05-07 | Boehringer Ingelheim Vetmed | Proteinas h5, de h5n1 para un uso medicinal |
| ES2689878T3 (es) * | 2013-02-21 | 2018-11-16 | Boehringer Ingelheim Vetmedica Gmbh | Proteínas H5 del virus de la gripe H5N1 para su uso como un medicamento |
| EP3039036B1 (en) | 2013-08-28 | 2019-05-22 | GlaxoSmithKline Biologicals S.A. | Novel influenza antigens and antibodies |
| WO2020093984A1 (en) * | 2018-11-06 | 2020-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Immunogenic composition against avian influenza virus h5 subtype |
| MX2019014943A (es) | 2018-12-12 | 2020-08-06 | Cambridge Tech Llc | Vacuna universal contra la gripe. |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4552758A (en) | 1983-12-20 | 1985-11-12 | St. Jude Children's Research Hospital | Human use of avian-human reassortants as vaccines for influenza A virus |
| US6204281B1 (en) | 1998-07-10 | 2001-03-20 | Novartis Ag | Method of treatment and pharmaceutical composition |
| US20040071733A1 (en) | 2001-02-05 | 2004-04-15 | Hiroshi Takaku | Baculovirus vector vaccine |
| CA2456034A1 (en) | 2001-08-03 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Sustained-release medicines |
| CA2529647C (en) | 2003-06-16 | 2013-08-13 | Medimmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
| DE202005022108U1 (de) * | 2004-03-09 | 2013-11-12 | Novartis Vaccines And Diagnostics, Inc. | Influenza-Virus-Impfstoffe |
| CN1748795A (zh) | 2004-09-17 | 2006-03-22 | 金宁一 | 多价禽流感重组活载体疫苗 |
| KR20060089393A (ko) * | 2005-02-04 | 2006-08-09 | 주식회사 중앙백신연구소 | 돼지 인플루엔자 바이러스ａ／ｓｗｉｎｅ／ｋｏｒｅａ／ｓ83/2004(ｈ9ｎ2) 및 이의백신 |
| CN101193655A (zh) | 2005-04-11 | 2008-06-04 | 美国政府健康及人类服务部，疾病控制和预防中心 | 抗大流行性流感病毒株的疫苗 |
| US7871626B2 (en) | 2005-08-04 | 2011-01-18 | St. Jude Children's Research Hospital | Modified influenza virus for monitoring and improving vaccine efficiency |
| TW200731986A (en) | 2005-10-28 | 2007-09-01 | Boehringer Ingelheim Vetmed | Use of vaccines for the treatment/prevention of the transmission of pathogens |
| US8202967B2 (en) | 2006-10-27 | 2012-06-19 | Boehringer Ingelheim Vetmedica, Inc. | H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use |
-
2006
- 2006-10-27 TW TW095139655A patent/TW200731986A/zh unknown
- 2006-10-27 AT AT06836580T patent/ATE543512T1/de active
- 2006-10-27 BR BRPI0617952-5A patent/BRPI0617952A2/pt not_active IP Right Cessation
- 2006-10-27 CN CN2011103839490A patent/CN102406932A/zh active Pending
- 2006-10-27 AR ARP060104694A patent/AR056733A1/es not_active Withdrawn
- 2006-10-27 AU AU2006309007A patent/AU2006309007A1/en not_active Abandoned
- 2006-10-27 KR KR1020087012894A patent/KR20080065680A/ko not_active Application Discontinuation
- 2006-10-27 CN CNA2006800400455A patent/CN101300023A/zh active Pending
- 2006-10-27 JP JP2008537991A patent/JP2009513667A/ja active Pending
- 2006-10-27 CA CA002626866A patent/CA2626866A1/en not_active Abandoned
- 2006-10-27 US US11/553,492 patent/US8883123B2/en active Active
- 2006-10-27 EP EP06836580A patent/EP1942924B1/en active Active
- 2006-10-27 WO PCT/US2006/041989 patent/WO2007053446A2/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| EP1942924A2 (en) | 2008-07-16 |
| JP2009513667A (ja) | 2009-04-02 |
| US8883123B2 (en) | 2014-11-11 |
| CA2626866A1 (en) | 2007-05-10 |
| CN101300023A (zh) | 2008-11-05 |
| ATE543512T1 (de) | 2012-02-15 |
| KR20080065680A (ko) | 2008-07-14 |
| WO2007053446A2 (en) | 2007-05-10 |
| EP1942924B1 (en) | 2012-02-01 |
| BRPI0617952A2 (pt) | 2011-08-09 |
| WO2007053446A3 (en) | 2007-08-16 |
| CN102406932A (zh) | 2012-04-11 |
| AU2006309007A8 (en) | 2008-06-19 |
| AU2006309007A1 (en) | 2007-05-10 |
| TW200731986A (en) | 2007-09-01 |
| US20070207168A1 (en) | 2007-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056733A1 (es) | Uso de vacunas para el tratamiento / prevencion de la transmision de patogenos | |
| CL2019000415A1 (es) | Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéuticos de una infección por el virus del vih. | |
| EP4233898A3 (en) | Influenza mrna vaccines | |
| WO2018115527A3 (en) | Mers coronavirus vaccine | |
| CL2017000285A1 (es) | Terapia combinada para el tratamiento de un paramixovirus | |
| CY1117673T1 (el) | Ανασυνδυασμενα αντιγονα rsv | |
| CL2016000650A1 (es) | Composicion de vacuna que comprende un antigeno y una formulacion coadyuvante, que comprende al menos el 50 % v/v de una fase oleosa, monofosforil-lipido a (mpl-a) o un analogo del mismo y un oligonucleotido inmunoestimulate; y uso de la composición de vacuna para preparar un medicamento. | |
| CL2016002372A1 (es) | Cenicriviroc para el tratamiento de la fibrosis. | |
| MX2020004543A (es) | Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan. | |
| BR112017002370A2 (pt) | indóis para uso na infecção pelo vírus da gripe | |
| CL2017001961A1 (es) | Vacuna bivalente contra el virus de gripe porcina | |
| AR065319A1 (es) | Prevencion y tratamiento de pcvd subclinica | |
| CO6190623A2 (es) | Vacuna salmonella | |
| EA200970013A1 (ru) | Вакцинация против гриппа по схеме многократного введения с использованием безадъювантной дозы | |
| CL2011001993A1 (es) | Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio; metodo de produccion; y su uso para prevenir, mejorar o tratar una enfermedad productiva por el virus del dengue en un sujeto. | |
| CL2011000877A1 (es) | Composicion inmunogena para el tratamiento y/o profilaxis de ganado contra infecciones microbiologicas porque comprende antigeno de mycoplasma bovis; metodo de coadministracion de dos o mas antigenos a un ganado bovino. | |
| AR121361A1 (es) | Vacuna | |
| CL2019001275A1 (es) | Atenuación de virulencia bacteriana mediante atenuación de transporte de folato bacteriano. | |
| UY32715A (es) | Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados | |
| DOP2016000336A (es) | Derivados de isoindolina para uso en el tratamiento de una infeccion viral | |
| AR108829A1 (es) | Vacuna contra virus de bronquitis infecciosa | |
| UY32720A (es) | Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados | |
| CL2009001195A1 (es) | Adyuvante inmune que comprende un inhibidor de iap capaz de modular la actividad inmune; composicion farmaceutica y vacuna que lo comprenden; metodo para mejorar una respuesta inmune de un individuo; metodo para tratar un cancer en un individuo; metodo para tratar infeccion; metodo para tratar trastornos autoinmune. | |
| CL2018001946A1 (es) | Virus atenuados de bronquitis infecciosa. | |
| AR052639A1 (es) | Composicion vacunal contra el virus de la hepatitis c. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |